Prof. Hugues Chabriat and Dr. Dominique Hervé, Neurologists from CERVCO, participated as speakers at the International Stroke Conference 2025, held from February 5 to 7, 2025, at the Los Angeles Convention Center.
This annual event brings together leading experts from around the world to discuss the latest advancements in cerebrovascular diseases.
🔬 Focus on Prof. Hugues Chabriat’s Session
Prof. Chabriat spoke at a symposium dedicated to Cerebral Small Vessel Disease (CSVD). He particularly highlighted CADASIL, the most common monogenic form of CSVD, exploring its clinical manifestations, imaging characteristics, genetic basis, and known biomarkers. By comparing CADASIL with other monogenic forms of CSVD, this session aimed to enhance the understanding of the pathophysiology and clinical expression of these diseases, as well as to identify new diagnostic and therapeutic strategies.
🧬 Dr. Dominique Hervé participated in a joint session organized by the Japan Stroke Society and the American Stroke Association, focusing on the specificities of Moyamoya angiopathy in East Asia. One of the key explanations lies in the high prevalence of the p.R4810K variant in the RNF213 gene in this population (mainly Japan and Korea). Initially identified as a susceptibility gene for Moyamoya disease, this variant is now recognized as a major risk factor for intracranial arterial stenosis, including atherosclerotic forms. Alongside four other international experts, Dr. Hervé contributed to shedding light on the clinical implications of recent genetic advances in Moyamoya disease and future therapeutic perspectives.
CERVCO remains committed to research and innovation for the benefit of patients, sharing its expertise with the global scientific community.
